Superstring Capital Management Lp

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$140.0M
Q ending 2026-03-31
Prior quarter
$186.8M
Q ending 2025-12-31
Change
-25.1% QoQ · +66.5% YoY
Positions
35
reported holdings

Largest positions

All 35 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Summit Therapeutics IncSMMTShares$16.9M893K
Immunovant IncIMVTShares$8.9M358K
Cogent Biosciences IncCOGTShares$8.7M225K
Savara IncSVRAShares$8.7M1.6M
Urogen Pharma LtdShares$7.0M387K
Definium Therapeutics IncDFTXShares$6.6M351K
Vir Biotechnology IncVIRShares$6.5M731K
Vaxcyte IncPCVXShares$6.4M110K
Celldex Therapeutics Inc NewCLDXShares$5.7M180K
Sionna Therapeutics IncSIONShares$5.7M141K
Genmab A/SGMABShares$5.3M197K
Zai Lab LtdZLABShares$5.2M276K
Vertex Pharmaceuticals IncVRTXShares$4.9M11K
Iqvia Hldgs IncIQVShares$4.4M26K
Maplight Therapeutics IncMPLTShares$3.9M192K
Arvinas IncARVNShares$3.3M313K
Oruka Therapeutics IncORKAShares$3.1M64K
United Therapeutics Corp DelUTHRShares$3.1M5K
Travere Therapeutics IncTVTXShares$3.1M103K
Trevi Therapeutics IncTRVIShares$3.0M252K
Adlai Nortye LtdANLShares$2.9M415K
Cabaletta Bio IncCABAShares$2.9M1.1M
Pfizer IncPFEShares$2.1M74K
Axsome Therapeutics Inc.AXSMShares$1.9M11K
Oric Pharmaceuticals IncORICShares$1.5M115K
Aclaris Therapeutics IncACRSShares$1.4M366K
Climb Bio IncCLYMShares$1.4M199K
Taysha Gene Therapies IncTSHAShares$1.2M258K
Bright Minds Biosciences IncDRUGShares$971K13K
Tonix Pharmaceuticals Hldg CTNXPShares$874K64K
Cullinan Therapeutics IncCGEMShares$845K59K
Protara Therapeutics IncTARAShares$633K121K
Palatin Technologies IncPTNShares$627K36K
Biomea Fusion IncBMEAShares$383K250K
Century Therapeutics IncIPSCShares$270K119K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.